Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
|ClinicalTrials.gov Identifier: NCT00763295|
Recruitment Status : Completed
First Posted : September 30, 2008
Last Update Posted : October 26, 2012
HIV infection highly increases the risk of progression of latent tuberculosis (TB) to active disease that therapy is recommended for all PPD-positive, HIV-infected patients, regardless of age. Sensitivity of the PPD testing is, however, dependent on a normal T cell function.
Therefore, an accurate and reliable method for detection of latent tuberculosis in patients with HIV is urgently needed.
This prospective study will examine the utility of interferon-gamma (IFN-γ) based assay, T-SPOT.TB,for detection of TB in HIV-infected individuals.
|Condition or disease||Intervention/treatment|
|Latent Tuberculosis HIV Infections||Other: T-Spot.TB test|
|Study Type :||Observational|
|Actual Enrollment :||53 participants|
|Observational Model:||Case Control|
|Official Title:||Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||January 2010|
Other: T-Spot.TB test
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763295
|United States, New York|
|Staten Island University Hospital|
|Staten Island, New York, United States, 10305|